Researchers at Johns Hopkins found that fragments of tumor DNA can appear in the bloodstream up to three years before a cancer diagnosis, offering a potentially revolutionary window for early ...

Ginger vs. Cancer: Natural compound targets tumor metabolism Suppression of de novo fatty acid synthesis with ethyl p-methoxycinnamate found to inhibit tumor cell growth Date: June 10, 2025 Source ...

Karla Flores was diagnosed with a rare brain tumor. A misplaced MRI found a second, nearly inoperable, tumor on her spine.

The process of necrosis, a form of cell death, may represent one of the most promising ways to change the course of human aging, disease and even space travel, according to a new study from ...

Menarini Group Presents Updated Data Underscoring the Combinability of Elacestrant (ORSERDU®) in Patients with ER+, HER2- Metastatic Breast Cancer (mBC) at the ASCO 2025 Annual Meeting ...

Clonal hematopoiesis of indeterminate potential (CHIP) is an age-related condition associated with increased mortality among patients with cancer. CHIP mutations with high variant-allele frequencie ...

This patent application pertains to macrocyclic peptides, generally represented by Formula I. These compounds exhibit selective binding to tumor necrosis factor receptor 1 (TNFR1) and hold the ...

An exclusive licensing agreement with Insilico Medicine Inc. grants Menarini’s Stemline Therapeutics Inc. the global rights to develop and commercialize a preclinical small molecule for high unmet ...

Another new year, another half-billion-biobuck transaction between Insilico Medicine and the Italian drugmaker Menarini Group. | Their second exclusive, global in-licensing covers a second small ...

Prior to this collaboration, the Menarini Group and Insilico entered an exclusive licensing agreement in January 2024 for MEN2312, an innovative small molecule for breast cancer treatment and ...

Menarini Group and Insilico Medicine enter a second exclusive global license agreement for an AI discovered preclinical asset targeting high unmet needs in oncology ...

Under the commercial agreement, A. Menarini Diagnostics will assume exclusive marketing of the non-invasive Bladder EpiCheck® test in Europe in the months ahead, providing patients and clinicians ...